pharmaceutical management of patient with Covid-19

/in /by

pharmaceutical management of patient with Covid-19

nclude a brief pathophysiology of COVID-19 -19, is it a viral or bacterial infection? investigational drug such as Remdesivir (Veklury), Hydroxychloroquine, Chloroquine, Dexamethasone, and the latest Vaccine. The paper will be a minimum of five pages and must be APA format.

Hello, this is what I need help with. You will need to write a paper on the pharmaceutical management of patient with Covid-19. Include a brief pathophysiology of COVID-19 -19, is it a viral or bacterial infection? investigational drug such as Remdesivir (Veklury), Hydroxychloroquine, Chloroquine, Dexamethasone, and the latest Vaccine. Please create a Concept map for each of the above drug. The paper will be a minimum of five pages and must be APA format.

2 Attachments
Answer preview

                Different medications are available for the management of the Coronavirus disease 19 (COVID-19) infection. The infection is caused by the severe syndrome respiratory syndrome coronavirus-2(SARS-CoV-2) virus with high transmission, morbidity, and mortality threats. The infection causes a wide range of symptoms, including fever, cough, headache, chills, fatigue, body aches, and runny nose. The FDA has approved different COVID-19 treatment medications, including Remdesivir (Veklury), and made others available through the FDA emergency use authorization (EUA) Hydroxychloroquine, Chloroquine, and Dexamethasone (CDC, 2020, June 27). For the patient at high risk of progression, medication to treat different diseases will avert a serious illness. COVAX (led by the WHO, GAVI, and CEPI) has also approved the BNT162b2 mRNA Covid-19 Vaccine and expects it to be finalized by June 2021, and the assessment of core data is in progress (COVID_VAX. (2020, December 28). Amidst continuous trials to assess the effectiveness of various medications, they are effective and safe for managing the condition. Some of the agents are specified for outpatient intravenous intervention, and the application is configured for a given location to safely manage the patient (NIH, 2020, December 3). This plan outlines a COVID-19 patient’s pharmaceutical management using Remdesivir (Veklury), Hydroxychloroquine, Chloroquine, and Dexamethasone BNT162b2 mRNA Covid-19 Vaccine. The FDA approved medication, those made available through EUA, and the vaccine are important since they prove effective and safe in treatment and prevention interventions to improve patients’ healthcare outcomes.

(1795words)